Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Endocrine 114CNS 21Sarcoma 5Head & Neck 4Dermatologic 4Thoracic 3Other hematologic neoplasm 3Lymphoid 3Genitourinary 2Gastrointestinal 2Breast 2Other solid neoplasm 1NET 1Gynecologic 1

Conditions

Neuroendocrine Tumors 394Carcinoid Tumor 49Gastro-enteropancreatic neuroendocrine tumor 42Neoplasms 36Carcinoma, Neuroendocrine 36Adenoma, Islet Cell 27Neoplasm Metastasis 23Pancreatic Neoplasms 22Colorectal Neoplasms 21Pheochromocytoma 20Paraganglioma 19Sarcoma 15Gastrointestinal Neoplasms 15Carcinoma 14Breast Neoplasms 14Stomach Neoplasms 13Prostatic Neoplasms 13Neuroblastoma 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Thyroid Neoplasms 12Small Cell Lung Carcinoma 12Carcinoma, Renal Cell 11Cholangiocarcinoma 10Neuroectodermal Tumors, Primitive 9Carcinoma, Non-Small-Cell Lung 9Somatostatinoma 8Serotonin Syndrome 8Digestive System Neoplasms 8Brain Neoplasms 8

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pituitary Neoplasms × NET × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡